Denca is under control at SAFC plant in Scotland

Published: 6-Jun-2011
Manufacturing Pharmaceutical

Will supply full control system for IPB2 facility at Irvine

Automation control systems specialist Denca Controls has been awarded the E&I controls contract for the new IPB2 facility being designed by laboratory and cleanroom specialist T Squared for SAFC, a leader in biochemical and organic chemical products, based in Irvine, Scotland.

The project involves building and automating a cell culture media, reagents and buffer solutions manufacturing system, CIP system, WFI/SIP system and filling system at the SAFC facility.

Denca, based in Widnes, Cheshire, will supply a full control system consisting of E&I design, manufacture of system control panels, including motor control panel, PLC/instrument control panel and multiple remote I/O, solenoid, HMI panels, system software and associated validation documentation to GAMP (Good Automated Manufacturing Practices), installation and testing/commissioning through to client handover.

See more

You may also like

Manufacturing

Denca designs control system for pharma facility

Read more
Project in Liverpool worth £500,000

Trending Articles

  1. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  2. Japanese pharma companies shifting to earlier CDMO outsourcing as peptide complexity increases Neuland Laboratories has reported a notable shift in Japanese pharmaceutical outsourcing patterns during the past 12-24 months, with companies engaging CDMOs earlier in the development cycle
  3. UK REACH reform falls short as industry warns of £500m+ compliance bill The UK chemicals industry has condemned the Government's long-awaited response to the UK REACH Alternative Transitional Registration model consultation, arguing it does little to support growth or innovation

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Denca designs control system for pharma facility

Project in Liverpool worth £500,000
Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Regulatory

FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection

The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026
Manufacturing

Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform

The pair will work to enhance CAR NK cell therapy manufacturing efficiency, combining Miltenyi Bioindustry's baboon envelope lentiviral vector platform with CHA Biotech's NK cell research expertise to improve gene delivery, scalability and cost of goods
Manufacturing

Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services collaborate to support ADC development and manufacturing

Piramal and Ajinomoto Bio-Pharma Services have entered a collaborative arrangement aimed at enhancing their customers’ ADC development and manufacturing programs
Manufacturing

Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market

Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA
Manufacturing

Japanese pharma companies shifting to earlier CDMO outsourcing as peptide complexity increases

Neuland Laboratories has reported a notable shift in Japanese pharmaceutical outsourcing patterns during the past 12-24 months, with companies engaging CDMOs earlier in the development cycle
Subscribe now